Overview Safety, Tolerability, and Pharmacokinetic Study of Single Ascending Dose of GV101 in Healthy Subjects Status: Recruiting Trial end date: 2022-01-01 Target enrollment: Participant gender: Summary This is a single center Phase 1, placebo-controlled, randomized, double blind, first-in-human (FIH), sequential single ascending dose (SAD) study. Phase: Phase 1 Details Lead Sponsor: Graviton Bioscience Corporation